MARKET

ACOR

ACOR

Acorda
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.580
-0.040
-2.47%
Closed 16:00 11/19 EST
OPEN
1.600
PREV CLOSE
1.620
HIGH
1.690
LOW
1.570
VOLUME
979.79K
TURNOVER
--
52 WEEK HIGH
21.13
52 WEEK LOW
1.570
MARKET CAP
75.89M
P/E (TTM)
-0.2184
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACOR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ACOR News

  • Acorda Therapeutics Announces Departure of President, International & General Counsel
  • Business Wire.11/12 12:00
  • Is Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Paid Enough Relative To Peers?
  • Simply Wall St..11/08 15:21
  • Biotech Stock On The Radar: Alkermes At A Crossroads
  • Benzinga.11/07 16:54
  • Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales
  • Zacks.11/07 16:08

More

Industry

Biotechnology & Medical Research
+2.16%
Pharmaceuticals & Medical Research
+0.78%

Hot Stocks

Name
Price
%Change

About ACOR

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
More

Webull offers Acorda Therapeutics Inc (ACOR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.